Giant cell tumor of is a benign but aggressive tumor of the bone, most frequently seen in the third decade and generally localized in the metaphases of the long bones after the physeal closure. The excentric lytic lesion causes cortical expansion as well as thinning, and the tumor may also have a soft tissue component. Nearly 25% local recurrence is seen in spite of the treatment modalities such as intralesional curettage, local adjuvant usage after high speed burring, and bone cement. In recent years, recognition of pathologic properties of the tumor as well as the , molecular and genetic such as nuclear factor kappa B (NF-κB) ligand receptor activator (RANKL) has defined new targets in the treatment of the giant cell tumor. The use of denosumab, which is the human monoclonal antibody of RANKL, has provided treatment without surgery and decreased the recurrence rate after surgery.